SITE010-0094

SITE010 (ESP) › SITE010-0094

SITE010-0094

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2025-12-29

completed

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 77); relationship: NOT RELATED

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 77); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-17 (study day 16); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.